Replies to post #56 on Mawson Infrastructure Group Inc (MIGI)

[midastouch017]

Ophthalix has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems; terms not disclosed (OPLI) : I.V.S. develops breakthrough medical device technologies to improve sight, diagnose and offer therapy for a variety of ocular diseases including glaucoma, age related macular degeneration (AMD), diabetic retinopathy and oculo-motor pathologies. OphthaliX announced it is committed to continuing its development program for its drug candidate CF101, a neuro-protective and anti-inflammatory drug, for the treatment of glaucoma. Patients are currently enrolled for the second segment of the Phase II study and are treated orally with CF101.